We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||41.79 x 1300|
|Ask||41.87 x 1300|
|Day's Range||41.21 - 41.53|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||41.62|
|Earnings Date||Feb 01, 2017 - Feb 06, 2017|
|Forward Dividend & Yield||1.89 (4.61%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||47.70|
Biden chooses Kamala Harris as VP, the UK economy experienced the sharpest fall in Europe, mass mail-in voting faces logistical headaches, and other news to start your day.
Vir Biotechnology Inc said on Tuesday it plans to start a mid-to-late stage trial of its COVID-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus. The company's therapy candidate, VIR-7831, is a monoclonal antibody that binds itself to the SARS-CoV-2 live virus and neutralizes it. Vir Biotech expects initial clinical data from the study to be available before the end of 2020.
GlaxoSmithKline plc (LON:GSK) stock is about to trade ex-dividend in three days. This means that investors who...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of GlaxoSmithKline plc and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.
One benefit of a higher infection rate is that it could speed the conclusion of vaccine tests now under way. The first results could come as early as October, analysts say.
(GSK)’s head of cancer research says the U.S. Food and Drug Administration’s approval of the company’s new multiple myeloma drug is a validation of a yearslong process of reworking the company’s oncology pipeline, and a sign of more to come. “Oncology is back at GSK, is probably a fair thing to say,” says Axel Hoos, Glaxo’s senior vice president for oncology research and development. The drug, called belantamab mafodotin, is for use in only the sickest multiple myeloma patients, for whom at least four earlier treatments have not worked.
|Upgrade||UBS: Neutral to Buy||11/21/2019|
|Maintains||Argus Research: to Buy||11/11/2019|
|Upgrade||New Street: Reduce to Hold||10/16/2019|
|Upgrade||Cantor Fitzgerald: Hold to Buy||10/11/2019|
|Upgrade||Societe Generale: Sell to Buy||9/3/2019|
|Downgrade||Exane BNP Paribas: Outperform to Neutral||1/14/2019|
Industry: Drug Manufacturers—General
Full Time Employees: 99,437
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.